Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanism-based neuropharmacological and anatomical evidence without human trial data
PubMed 17049611 · doi:10.1016/j.pharmthera.2006.08.004
What was done
This narrative review synthesizes anatomical and neuropharmacological literature regarding how serotonin (5-HT) receptor subtypes regulate dopamine (DA) neurotransmission across the three major dopaminergic pathways, and discusses implications for schizophrenia, depression, and drug abuse.
What was found
The abstract reports qualitative mechanistic relationships and provides no numerical data or effect sizes. Subtypes 5-HT1A, 5-HT1B, 5-HT2A, 5-HT3, and 5-HT4 facilitate DA release, whereas 5-HT2C mediates an inhibitory effect. While most subtypes modulate DA release only when neurons are stimulated, 5-HT2C exhibits high constitutive activity that inhibits both tonic and evoked DA release.
Why it matters
Clarifying how specific serotonin receptor subtypes modulate dopamine pathways outlines mechanistic targets for pharmacotherapies in psychiatric and substance use disorders.
Limits
This is a narrative review lacking systematic search methodology or study counts. Findings are derived predominantly from preclinical neuroanatomical and animal pharmacology studies, limiting direct clinical generalizability.
Cited by
- context SSRIs increase levels of serotonin, but that serotonin is often utilized at dopamine synapses to reduce the rewarding properties of dopamine.